SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Suraj A. Sharma, Jordan J. Feld, Acute Hepatitis C: Management in the Rapidly Evolving World of HCV, Current Gastroenterology Reports, 2014, 16, 2

    CrossRef

  2. 2
    Hiroki Nishikawa, Hirayuki Enomoto, Akihiro Nasu, Nobuhiro Aizawa, Masaki Saito, Akihiro Tamori, Norifumi Kawada, Toru Kimura, Yukio Osaki, Shuhei Nishiguchi, Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy, Hepatology Research, 2014, 44, 8
  3. 3
    Deepak Joshi, Ivana Carey, Matthew Foxton, Mohammed Al-Freah, Matthew Bruce, Nigel Heaton, Alberto Quaglia, John O'Grady, Varuna Aluvihare, Kosh Agarwal, CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response, Clinical Transplantation, 2014, 28, 5
  4. 4
    Chia-Hsin Chen, Chau-Zen Wang, Yan-Hsiung Wang, Wei-Ting Liao, Yi-Jen Chen, Chang-Hung Kuo, Hsuan-Fu Kuo, Chih-Hsing Hung, Effects of Low-Level Laser Therapy on M1-Related Cytokine Expression in Monocytes via Histone Modification, Mediators of Inflammation, 2014, 2014, 1

    CrossRef

  5. 5
    Yusi Zhang, Bei Liu, Ying Ma, Jing Yi, Chunmei Zhang, Yun Zhang, Zhuwei Xu, Jiuping Wang, Kun Yang, Angang Yang, Ran Zhuang, Boquan Jin, Hantaan Virus Infection Induces CXCL10 Expression through TLR3, RIG-I, and MDA-5 Pathways Correlated with the Disease Severity, Mediators of Inflammation, 2014, 2014, 1

    CrossRef

  6. 6
    Carla Krueger, Mark Collister, Gerald Y. Minuk, Alyssa Janke, Jordyn Lerner, Stephen G. M. Wong, Julia D. Rempel, HCV protein-induced cytokine predicts treatment outcomes in chronic hepatitis C virus infection, Liver International, 2014, 34, 6
  7. 7
    David A. Sheridan, Simon H. Bridge, Mary M. E. Crossey, Daniel J. Felmlee, Fiona I. Fenwick, Howard C. Thomas, R. Dermot G. Neely, Simon D. Taylor-Robinson, Margaret F. Bassendine, Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy – a pilot randomised clinical trial, Liver International, 2014, 34, 5
  8. 8
    Clémence Arnaud, Christian Trépo, Marie-Anne Petit, Predictors of the therapeutic response in hepatitis C. A 2013 update, Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 1, 12

    CrossRef

  9. 9
    Kentaro Matsuura, Tsunamasa Watanabe, Sayuki Iijima, Shuko Murakami, Kei Fujiwara, Etsuro Orito, Etsuko Iio, Mio Endo, Atsunori Kusakabe, Noboru Shinkai, Tomokatsu Miyaki, Shunsuke Nojiri, Takashi Joh, Yasuhito Tanaka, Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C, Hepatology Research, 2014, 44, 8
  10. 10
    Jordan J. Feld, The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?, Antiviral Research, 2014, 105, 32

    CrossRef

  11. 11
    L. Covolo, S. Bibert, F. Donato, P.-Y. Bochud, M. Lagging, F. Negro, G. Fattovich, The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection, Alimentary Pharmacology & Therapeutics, 2014, 39, 3
  12. 12
    Lin-Jiao Chen, Juan Lv, Xiao-Yu Wen, Jun-Qi Niu, CXC chemokine IP-10: a key actor in liver disease?, Hepatology International, 2013, 7, 3, 798

    CrossRef

  13. 13
    Dina Ragab, Melissa Laird, Darragh Duffy, Armanda Casrouge, Rasha Mamdouh, Amal Abass, Dina El. Shenawy, Abdelhadi M. Shebl, Wagdi F. Elkashef, Khaled R. Zalata, Mostafa Kamal, Gamal Esmat, Philippe Bonnard, Arnaud Fontanet, Mona Rafik, Matthew L. Albert, CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients, Cytokine, 2013, 63, 2, 105

    CrossRef

  14. 14
    Hideyuki Konishi, Ken Shirabe, Shohei Yoshiya, Tetsuo Ikeda, Toru Ikegami, Tomoharu Yoshizumi, Ayae Ikawa-Yoshida, Takashi Motomura, Takasuke Fukuhara, Yoshihiko Maehara, Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C, Hepatology Research, 2013, 43, 11
  15. 15
    Anushree Chatterjee, Patrick F. Smith, Alan S. Perelson, Hepatitis C Viral Kinetics, Clinics in Liver Disease, 2013, 17, 1, 13

    CrossRef

  16. 16
    Marija Zeremski, Rositsa B. Dimova, Jessy Makeyeva, John D. Sipley, Ira M. Jacobson, Hanna Rennert, Andrew H. Talal, IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 63, 1, 9

    CrossRef

  17. 17
    Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Michele Colaci, Dilia Giuggioli, Giovanna Saraceno, Salvatore Benvenga, Clodoveo Ferri, Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10, Journal of Interferon & Cytokine Research, 2013, 33, 12, 739

    CrossRef

  18. 18
    Jason Grebely, Jordan J. Feld, Tanya Applegate, Gail V. Matthews, Margaret Hellard, Alana Sherker, Kathy Petoumenos, Geng Zang, Ineke Shaw, Barbara Yeung, Jacob George, Suzy Teutsch, John M. Kaldor, Vera Cherepanov, Julie Bruneau, Naglaa H. Shoukry, Andrew R. Lloyd, Gregory J. Dore, Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection, Hepatology, 2013, 57, 6
  19. 19
    Camelia Sultana, Simona Manuela Erscoiu, Camelia Grancea, Emanoil Ceausu, Simona Ruta, Predictors of Chronic Hepatitis C Evolution in HIV Co-Infected Patients From Romania, Hepatitis Monthly, 2013, 13, 2

    CrossRef

  20. 20
    Martin Lagging, Karolina Rembeck, Mads Rauning Buhl, Peer Christensen, Olav Dalgard, Martti Färkkilä, Kristoffer Hellstrand, Nina Langeland, Magnus Lindh, Johan Westin, Gunnar Norkrans, Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse, Scandinavian Journal of Gastroenterology, 2013, 48, 7, 839

    CrossRef

  21. 21
    I-Cheng Lee, Yi-Hsiang Huang, Gar-Yang Chau, Teh-Ia Huo, Chien-Wei Su, Jaw-Ching Wu, Han-Chieh Lin, Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments, International Journal of Cancer, 2013, 133, 12
  22. 22
    Milan J. Sonneveld, Pauline Arends, Andre Boonstra, Bettina E. Hansen, Harry L.A. Janssen, Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B, Journal of Hepatology, 2013, 58, 5, 898

    CrossRef

  23. 23
    Golo Ahlenstiel, The Natural Killer Cell Response to HCV Infection, Immune Network, 2013, 13, 5, 168

    CrossRef

  24. 24
    David A. Sheridan, Simon H. Bridge, Daniel J. Felmlee, Mary M.E. Crossey, Howard C. Thomas, Simon D. Taylor-Robinson, Geoffrey L. Toms, R. Dermot G. Neely, Margaret F. Bassendine, Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity, Journal of Hepatology, 2012, 57, 1, 32

    CrossRef

  25. 25
    Ivan Kurelac, Snjezana Zidovec Lepej, Ivana Grgic, Lana Gorenec, Neven Papic, Davorka Dusek, Bruno Barsic, Adriana Vince, Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C, Journal of Interferon & Cytokine Research, 2012, 32, 8, 386

    CrossRef

  26. 26
    Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Marco Sebastiani, Andreina Manfredi, Valeria Mazzi, Silvia Fabiani, Marco Centanni, Santino Marchi, Clodoveo Ferri, Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis, Modern Rheumatology, 2012, 22, 5, 659

    CrossRef

  27. 27
    Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Marco Sebastiani, Andreina Manfredi, Valeria Mazzi, Silvia Fabiani, Marco Centanni, Santino Marchi, Clodoveo Ferri, Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis, Modern Rheumatology, 2012, 22, 5, 659

    CrossRef

  28. 28
    Michelle Lai, Nezam H. Afdhal, Clinical utility of interleukin-28B testing in patients with genotype 1, Hepatology, 2012, 56, 1
  29. 29
    Liz Alvarez-Lajonchere, Santiago Dueñas-Carrera, Complete Definition of Immunological Correlates of Protection and Clearance of Hepatitis C Virus Infection: A Relevant Pending Task for Vaccine Development, International Reviews of Immunology, 2012, 31, 3, 223

    CrossRef

  30. 30
    A. Casrouge, A. Bisiaux, L. Stephen, M. Schmolz, J. Mapes, C. Pfister, S. Pol, V. Mallet, M. L. Albert, Discrimination of agonist and antagonist forms of CXCL10 in biological samples, Clinical & Experimental Immunology, 2012, 167, 1
  31. 31
    Stéphanie Dabo, Eliane Meurs, dsRNA-Dependent Protein Kinase PKR and its Role in Stress, Signaling and HCV Infection, Viruses, 2012, 4, 12, 2598

    CrossRef

  32. 32
    Emilie Estrabaud, Michel Vidaud, Patrick Marcellin, Tarik Asselah, Genomics and HCV infection: Progression of fibrosis and treatment response, Journal of Hepatology, 2012, 57, 5, 1110

    CrossRef

  33. 33
    Emmanuel Thomas, Veronica D. Gonzalez, Qisheng Li, Ankit A. Modi, Weiping Chen, Mazen Noureddin, Yaron Rotman, T. Jake Liang, HCV Infection Induces a Unique Hepatic Innate Immune Response Associated With Robust Production of Type III Interferons, Gastroenterology, 2012, 142, 4, 978

    CrossRef

  34. 34
    Martin Lagging, Impact ofIL28BSNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes, Pharmacogenomics, 2012, 13, 8, 847

    CrossRef

  35. 35
    Michela E Burlone, Rosalba Minisini, Mario Pirisi, Interferon-stimulated gene pathways in the treatment of viral hepatitis, Future Virology, 2012, 7, 4, 361

    CrossRef

  36. 36
    Eleonora Aricò, Filippo Belardelli, Interferon-α as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response Signature, Journal of Interferon & Cytokine Research, 2012, 32, 6, 235

    CrossRef

  37. 37
    Paul J. Clark, Andrew J. Muir, Lost in translation? IL28B's discovery and the journey back to the patient, Hepatology, 2012, 56, 1
  38. 38
    Victoria O Kasprowicz, John S Halliday, Jessica Mitchell, Paul Klenerman, MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-γ release assays, Biomarkers in Medicine, 2012, 6, 2, 177

    CrossRef

  39. 39
    Hamad I. Al-Ashgar, Mohammed Q. Khan, Ahmed Helmy, Sahar Al-Thawadi, Mohammed N. Al-Ahdal, Nisreen Khalaf, Ahmed Al-Qahtani, Faisal M Sanai, Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4, European Journal of Gastroenterology & Hepatology, 2012, 1

    CrossRef

  40. 40
    Y. Kishida, N. Imaizumi, H. Tanimura, Y. Haruna, S. Kashiwamura, T. Kashiwagi, Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  41. 41
    Sandra Beinhardt, Judith H. Aberle, Michael Strasser, Emina Dulic–Lakovic, Andreas Maieron, Anna Kreil, Karoline Rutter, Albert F. Staettermayer, Christian Datz, Thomas M. Scherzer, Robert Strassl, Martin Bischof, Rudolf Stauber, Gerd Bodlaj, Hermann Laferl, Heidemarie Holzmann, Petra Steindl–Munda, Peter Ferenci, Harald Hofer, Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection, Gastroenterology, 2012, 142, 1, 78

    CrossRef

  42. 42
    Karla J Helbig, Michael R Beard, The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment, Biomarkers in Medicine, 2012, 6, 2, 141

    CrossRef

  43. 43
    Pierre-Alain Rubbo, Philippe Van de Perre, Edouard Tuaillon, The long way toward understanding host and viral determinants of therapeutic success in HCV infection, Hepatology International, 2012, 6, 2, 436

    CrossRef

  44. 44
    Martin Lagging, Ann-Sofi Duberg, Rune Wejstål, Ola Weiland, Magnus Lindh, Soo Aleman, Filip Josephson, Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations, Scandinavian Journal of Infectious Diseases, 2012, 44, 7, 502

    CrossRef

  45. 45
    Hannah M. Jones, Phylinda L. S. Chan, Piet H. van der Graaf, Robert Webster, Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C, British Journal of Clinical Pharmacology, 2012, 73, 1
  46. 46
    J. Florholmen, M. G. Kristiansen, S. E. Steigen, S. W. Sørbye, E. J. Paulssen, J. M. Kvamme, Z. Konopski, T. Gutteberg, R. Goll, A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C, Clinical Microbiology and Infection, 2011, 17, 2
  47. 47
    Edgar D. Charles, Lynn B. Dustin, Chemokine antagonism in chronic hepatitis C virus infection, Journal of Clinical Investigation, 2011, 121, 1, 25

    CrossRef

  48. 48
    Wonseok Kang, Eui-Cheol Shin, Clinical Implications of Chemokines in Acute and Chronic Hepatitis C Virus Infection, Yonsei Medical Journal, 2011, 52, 6, 871

    CrossRef

  49. 49
    Eleonora Aricò, Luciano Castiello, Francesca Urbani, Paola Rizza, Monica C Panelli, Ena Wang, Francesco M Marincola, Filippo Belardelli, Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments, Journal of Translational Medicine, 2011, 9, 1, 67

    CrossRef

  50. 50
    Mingli Liu, Shanchun Guo, Jacqueline M. Hibbert, Vidhan Jain, Neeru Singh, Nana O. Wilson, Jonathan K. Stiles, CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications, Cytokine & Growth Factor Reviews, 2011,

    CrossRef

  51. 51
    Pam Kimball, Felecia McDougan, Richard Stirling, CXCR3 Expression Elevated on Peripheral CD8+Lymphocytes from HIV/HCV Coinfected Individuals, Viral Immunology, 2011, 24, 6, 441

    CrossRef

  52. 52
    Terence Chan, Frank Gu, Early diagnosis of sepsis using serum biomarkers, Expert Review of Molecular Diagnostics, 2011, 11, 5, 487

    CrossRef

  53. 53
    Armanda Casrouge, Jérémie Decalf, Mina Ahloulay, Cyril Lababidi, Hala Mansour, Anaïs Vallet-Pichard, Vincent Mallet, Estelle Mottez, James Mapes, Arnaud Fontanet, Stanislas Pol, Matthew L. Albert, Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV, Journal of Clinical Investigation, 2011, 121, 1, 308

    CrossRef

  54. You have free access to this content54
    Edward Gane, Future hepatitis C virus treatment: interferon-sparing combinations, Liver International, 2011, 31,
  55. 55
    Jan Grabowski, Cihan Yurdaydìn, Kalliopi Zachou, Peter Buggisch, Wolf P. Hofmann, Jerzy Jaroszewicz, Verena Schlaphoff, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment, Liver International, 2011, 31, 9
  56. 56
    G. Fattovich, L. Covolo, S. Bibert, G. Askarieh, M. Lagging, S. Clément, G. Malerba, M. Pasino, M. Guido, M. Puoti, G. B. Gaeta, T. Santantonio, G. Raimondo, R. Bruno, P.-Y. Bochud, F. Donato, F. Negro, IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2011, 33, 10
  57. 57
    Christian M. Lange, Stefan Zeuzem, IL28B single nucleotide polymorphisms in the treatment of hepatitis C, Journal of Hepatology, 2011, 55, 3, 692

    CrossRef

  58. 58
    Rositsa B. Dimova, Marianthi Markatou, Andrew H. Talal, Information methods for model selection in linear mixed effects models with application to HCV data, Computational Statistics & Data Analysis, 2011, 55, 9, 2677

    CrossRef

  59. 59
    Norman D. Grace, Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy, Clinical Gastroenterology and Hepatology, 2011, 9, 7, 536

    CrossRef

  60. 60
    Verónica Saludes Montoro, Vicente Ausina Ruiz, Elisa Martró Català, Posibilidades actuales para predecir la respuesta a la terapia en pacientes con hepatitis C crónica por el genotipo 1 del virus de la hepatitis C, Enfermedades Infecciosas y Microbiología Clínica, 2011, 29, 51

    CrossRef

  61. 61
    T. Kanda, F. Imazeki, Y. Yonemitsu, S. Mikami, N. Takada, T. Nishino, M. Takashi, A. Tsubota, K. Kato, N. Sugiura, A. Tawada, S. Wu, T. Tanaka, S. Nakamoto, R. Mikata, M. Tada, T. Chiba, T. Kurihara, M. Arai, K. Fujiwara, F. Kanai, O. Yokosuka, Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test, Journal of Viral Hepatitis, 2011, 18, 7
  62. 62
    Jama M. Darling, Jeroen Aerssens, Gregory Fanning, John G. McHutchison, David B. Goldstein, Alexander J. Thompson, Kevin V. Shianna, Nezam H. Afdhal, Michael L. Hudson, Charles D. Howell, Willem Talloen, Jacques Bollekens, Mieke De Wit, Annick Scholliers, Michael W. Fried, Quantitation of pretreatment serum interferon-γ–inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response, Hepatology, 2011, 53, 1
  63. 63
    Marie-Luise Berres, Christian Trautwein, Maximilian Schmeding, Dennis Eurich, Frank Tacke, Marcus Bahra, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth, Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection, Hepatology, 2011, 53, 2
  64. 64
    Suguru Yoneda, Takeji Umemura, Satoru Joshita, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Yoshihiko Katsuyama, Masao Ota, Eiji Tanaka, Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C, Hepatology Research, 2011, 41, 6
  65. 65
    Mark D. Gorrell, Amany Zekry, Geoffrey W. McCaughan, Andrew Lloyd, The long and the short of interferon-gamma–inducible protein 10 in hepatitis C virus infection, Hepatology, 2011, 54, 5
  66. 66
    E. S. Andersen, M. Ruhwald, B. Moessner, P. B. Christensen, O. Andersen, J. Eugen-Olsen, N. Weis, Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1, European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30, 6, 761

    CrossRef

  67. 67
    Ndiémé Ndongo, Pascale Berthillon, Pierre Pradat, Claude Vieux, Isabelle Bordes, Françoise Berby, Marianne Maynard, Fabien Zoulim, Christian Trépo, Marie-Anne Petit, Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus, Hepatology, 2010, 52, 5
  68. 68
    Hans Orlent, Isabelle Desombere, Bettina Hansen, Hans Van Vlierberghe, Bart Haagmans, Robert J. De Knegt, Solko W. Schalm, Geert Leroux-Roels, Harry L.A. Janssen, Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment, European Journal of Gastroenterology & Hepatology, 2010, 1

    CrossRef

  69. 69
    Pantxika Bellecave, Magdalena Sarasin-Filipowicz, Olivier Donzé, Audrey Kennel, Jérôme Gouttenoire, Etienne Meylan, Luigi Terracciano, Jürg Tschopp, Christoph Sarrazin, Thomas Berg, Darius Moradpour, Markus H. Heim, Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system, Hepatology, 2010, 51, 4
  70. 70
    Karolin Falconer, Galia Askarieh, Nina Weis, Kristoffer Hellstrand, Annette Alaeus, Martin Lagging, IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV, Scandinavian Journal of Infectious Diseases, 2010, 42, 11-12, 896

    CrossRef

  71. 71
    Y. ROTMAN, B. B. BORG, A. SOZA, J. J. FELD, A. A. MODI, R. LOOMBA, G. LUTCHMAN, E. RIVERA, E. DOO, M. G. GHANY, T. HELLER, A. U. NEUMANN, T. J. LIANG, J. H. HOOFNAGLE, Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response, Alimentary Pharmacology & Therapeutics, 2010, 31, 9
  72. 72
    François Bailly, Si Nafa Si Ahmed, Pierre Pradat, Christian Trepo, Management of nonresponsive hepatitis C, Expert Review of Anti-infective Therapy, 2010, 8, 4, 379

    CrossRef

  73. 73
    Edward J Gane, Stuart K Roberts, Catherine AM Stedman, Peter W Angus, Brett Ritchie, Rob Elston, David Ipe, Peter N Morcos, Linda Baher, Isabel Najera, Tom Chu, Uri Lopatin, M Michelle Berrey, William Bradford, Mark Laughlin, Nancy S Shulman, Patrick F Smith, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial, The Lancet, 2010, 376, 9751, 1467

    CrossRef

  74. 74
    Ana Vargas, Juan Berenguer, Pablo Ryan, Pilar Catalán, Juan Carlos López, Jaime Cosín, Pilar Miralles, Salvador Resino, Plasma Interferon-γ-Inducible Protein-10 Can Predict Virologic Response to Hepatitis C Virus Therapy in HIV/HCV-Coinfected Patients With HCV Genotype 1, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010, 54, 2, 219

    CrossRef

  75. 75
    Galia Askarieh, Åsa Alsiö, Paolo Pugnale, Francesco Negro, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Gunnar Norkrans, Johan Westin, Jonas Söderholm, Kristoffer Hellstrand, Martin Lagging, Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C, Hepatology, 2010, 51, 5
  76. 76
    Hugh G. Laverty, Daniel J. Antoine, Craig Benson, Masautso Chaponda, Dominic Williams, B. Kevin Park, The potential of cytokines as safety biomarkers for drug-induced liver injury, European Journal of Clinical Pharmacology, 2010, 66, 10, 961

    CrossRef

  77. 77
    R. E. Lanford, E. S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M. E. Munk, S. Kauppinen, H. Orum, Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection, Science, 2010, 327, 5962, 198

    CrossRef

  78. 78
    Harel Dahari, Jennifer E. Layden–Almer, Eric Kallwitz, Ruy M. Ribeiro, Scott J. Cotler, Thomas J. Layden, Alan S. Perelson, A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease, Gastroenterology, 2009, 136, 4, 1402

    CrossRef

  79. 79
    Mathis Heydtmann, David H. Adams, Chemokines in the immunopathogenesis of hepatitis C infection, Hepatology, 2009, 49, 2
  80. 80
    Alessandro Antonelli, Clodoveo Ferri, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Alessandro Pampana, Erica Panicucci, Angelo Carpi, Andrea Nicolini, Ele Ferrannini, CXCL10 and CCL2 Chemokine Serum Levels in Patients With Hepatitis C Associated With Autoimmune Thyroiditis, Journal of Interferon & Cytokine Research, 2009, 29, 6, 345

    CrossRef

  81. 81
    A. Antonelli, C. Ferri, P. Fallahi, S.M. Ferrari, S. Frascerra, F. Franzoni, F. Galetta, A.L. Zignego, E. Ferrannini, CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C, Digestive and Liver Disease, 2009, 41, 1, 42

    CrossRef

  82. 82
    Dolores B. Njoku, Zhaoxia Li, Jenelle L. Mellerson, Rajni Sharma, Monica V. Talor, Nicole Barat, Noel R. Rose, IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis, Journal of Autoimmunity, 2009, 32, 1, 52

    CrossRef

  83. 83
    Takeshi Okanoue, Yoshito Itoh, Hiroaki Hashimoto, Kohichiroh Yasui, Masahito Minami, Tetsuo Takehara, Eiji Tanaka, Morikazu Onji, Joji Toyota, Kazuaki Chayama, Kentaro Yoshioka, Namiki Izumi, Norio Akuta, Hiromitsu Kumada, Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study, Journal of Gastroenterology, 2009, 44, 9, 952

    CrossRef

  84. 84
    Alessandro Antonelli, Clodoveo Ferri, Poupak Fallahi, Silvia Martina Ferrari, Marco Sebastiani, Daniela Ferrari, Marco Giunti, Silvia Frascerra, Simone Tolari, Ferdinando Franzoni, Fabio Galetta, Santino Marchi, Ele Ferrannini, High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection, The American Journal of Gastroenterology, 2008, 103, 10, 2488

    CrossRef

  85. 85
    Alessandro Antonelli, Clodoveo Ferri, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Marco Sebastiani, Ferdinando Franzoni, Fabio Galetta, Ele Ferrannini, High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis, Cytokine, 2008, 42, 1, 137

    CrossRef

  86. 86
    He-Jun Yuan, William M Lee, Nonresponse to Treatment for Hepatitis C, Drugs, 2008, 68, 1, 27

    CrossRef

  87. 87
    Haruaki Shirakawa, Akihiro Matsumoto, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Kendo Kiyosawa, Eiji Tanaka, Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors, Hepatology, 2008, 48, 6
  88. 88
    Alessandro Antonelli, Clodoveo Ferri, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Angelo Carpi, Andrea Nicolini, Ele Ferrannini, α-Chemokine CXCL10 and β-chemokine CCL2 serum levels in patients with hepatitis C–associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis, Metabolism, 2008, 57, 9, 1270

    CrossRef

  89. 89
    Jordan J. Feld, Santosh Nanda, Ying Huang, Weiping Chen, Maggie Cam, Susan N. Pusek, Lisa M. Schweigler, Dickens Theodore, Steven L. Zacks, T. Jake Liang, Michael W. Fried, Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response, Hepatology, 2007, 46, 5
  90. 90
    Peter A.B. Wark, Fabio Bucchieri, Sebastian L. Johnston, Peter G. Gibson, Lynnsey Hamilton, Joanna Mimica, Giovanni Zummo, Stephen T. Holgate, John Attia, Ammarin Thakkinstian, Donna E. Davies, IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations, Journal of Allergy and Clinical Immunology, 2007, 120, 3, 586

    CrossRef

  91. 91
    Marija Zeremski, Marianthi Markatou, Queenie B Brown, Gary Dorante, Susanna Cunningham-Rundles, Andrew H Talal, Interferon ?????Inducible Protein 10, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007, PAP,

    CrossRef

  92. 92
    Nicholas A. Shackel, Geoffrey W. McCaughan, Intrahepatic interferon-stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?, Hepatology, 2007, 46, 5
  93. 93
    Robert E. Lanford, Bernadette Guerra, Catherine B. Bigger, Helen Lee, Deborah Chavez, Kathleen M. Brasky, Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus, Hepatology, 2007, 46, 4
  94. 94
    Golo Ahlenstiel, Hans Dieter Nischalke, Karin Bueren, Thomas Berg, Martin Vogel, Michael Biermer, Frank Grünhage, Tilman Sauerbruch, Jürgen Rockstroh, Ulrich Spengler, Jacob Nattermann, The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients, Journal of Hepatology, 2007, 47, 3, 348

    CrossRef

  95. 95
    Juan-Ramón Larrubia, Miryam Calvino, Selma Benito, Eduardo Sanz-de-Villalobos, Cristian Perna, Jaime Pérez-Hornedo, Fernando González-Mateos, Silvia García-Garzón, Antonio Bienvenido, Trinidad Parra, The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection, Journal of Hepatology, 2007, 47, 5, 632

    CrossRef